Todd B Sherer

Summary

Publications

  1. doi request reprint Overcoming obstacles in Parkinson's disease
    Todd B Sherer
    The Michael J Fox Foundation for Parkinson s Research, New York, New York 10163 4777, USA
    Mov Disord 27:1606-11. 2012
  2. ncbi request reprint Crossroads in GDNF therapy for Parkinson's disease
    Todd B Sherer
    Michael J Fox Foundation for Parkinson s Research, New York, New York 10005, USA
    Mov Disord 21:136-41. 2006
  3. doi request reprint Biomarkers for Parkinson's disease
    Todd B Sherer
    The Michael J Fox Foundation for Parkinson s Research, New York, NY 10004, USA
    Sci Transl Med 3:79ps14. 2011
  4. pmc Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs
    Marco A S Baptista
    Research Programs, The Michael J Fox Foundation for Parkinson s Research, New York, New York, United States of America
    PLoS ONE 8:e80705. 2013
  5. pmc A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's Research
    Marco A S Baptista
    The Michael J Fox Foundation for Parkinson s Research, New York, NY 10018 6798, USA
    Dis Model Mech 6:1316-24. 2013
  6. ncbi request reprint Oxidative damage in Parkinson's disease
    Todd B Sherer
    The Michael J Fox Foundation for Parkinson s Research, New York, NY, USA
    Antioxid Redox Signal 7:627-9. 2005

Collaborators

  • Anthony E Lang
  • J William Langston
  • Marco A S Baptista
  • Mark A Frasier
  • Brian K Fiske
  • Kuldip D Dave
  • Niketa P Sheth
  • George A Parker
  • Kirsten M Carlson
  • Melissa J Beck
  • Cindy Moore
  • Julie S Varsho
  • Yasmin N Aziz
  • Melanie Greeley
  • Shehan N De Silva
  • Madeline J Churchill
  • Charles K Meshul

Detail Information

Publications6

  1. doi request reprint Overcoming obstacles in Parkinson's disease
    Todd B Sherer
    The Michael J Fox Foundation for Parkinson s Research, New York, New York 10163 4777, USA
    Mov Disord 27:1606-11. 2012
    ..This review will discuss the most critical challenges in PD drug development and the innovative approaches being developed to overcome these hurdles...
  2. ncbi request reprint Crossroads in GDNF therapy for Parkinson's disease
    Todd B Sherer
    Michael J Fox Foundation for Parkinson s Research, New York, New York 10005, USA
    Mov Disord 21:136-41. 2006
    ..A critical review of available data suggests that there are questions that need to be answered before the future of GDNF as a therapy for PD can be determined...
  3. doi request reprint Biomarkers for Parkinson's disease
    Todd B Sherer
    The Michael J Fox Foundation for Parkinson s Research, New York, NY 10004, USA
    Sci Transl Med 3:79ps14. 2011
    ..Although some progress has been made, there are many challenges associated with developing biomarkers for detecting PD in its earliest stages...
  4. pmc Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs
    Marco A S Baptista
    Research Programs, The Michael J Fox Foundation for Parkinson s Research, New York, New York, United States of America
    PLoS ONE 8:e80705. 2013
    ..The characterization of LRRK2 knockout rats may prove to be extremely valuable in understanding potential safety liabilities of LRRK2 kinase inhibitor therapeutics for treating Parkinson's disease...
  5. pmc A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's Research
    Marco A S Baptista
    The Michael J Fox Foundation for Parkinson s Research, New York, NY 10018 6798, USA
    Dis Model Mech 6:1316-24. 2013
    ..Funding from MJFF, which subsidizes the costs involved in transfer, rederivation and colony expansion, has directly resulted in over 2500 rodents being distributed to the PD community for research use. ..
  6. ncbi request reprint Oxidative damage in Parkinson's disease
    Todd B Sherer
    The Michael J Fox Foundation for Parkinson s Research, New York, NY, USA
    Antioxid Redox Signal 7:627-9. 2005